Truist Securities Reiterates Buy on Tandem Diabetes Care, Lowers Price Target to $31
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price target from $35 to $31.
Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price target from $35 to $31.